Cures for hepatitis C virus (HCV) have been available for nearly five years, but many private insurers still aren’t paying for the lifesaving treatment, according to a new study published last week in Open Forum Infectious Diseases. A recent report by Gizmodo outlines the details.
The fight for access to hepatitis C treatment began in
Researchers at the University of Pennsylvania in Philadelphia recently set out to determine whether treatment rates have improved over the years since the cures first became available.
For the study, researchers examined the hepatitis C treatment prescriptions of more than 9,000 patients submitted between January 2016 and April 2017 to a specialty pharmacy that services 45 states. Overall, 35 percent of hep C prescriptions were flat-out denied. Patients on private insurance had a 52.4 percent denial rate, compared with 34.5 percent for Medicaid patients and 14.7 percent for those on Medicare.
“We thought things were going to improve,” said senior study author Vincent Lo Re, MD, an associate professor of Infectious Disease and Epidemiology at the University of Pennsylvania, noting that he and his team published a similar study on hep C drug coverage in 2015. “But despite the availability of new
Nevertheless, there is hope for eliminating the virus across the country if treatment rates pick up. A 2016 report from the National Academies of Sciences estimated that hepatitis C could be eliminated nationwide by 2030 as long as at least 260,000 people receive treatment every year. However, current estimates report that less than 10 percent of the at least 3.5 million Americans living with HCV have received treatment so far.